Pruritus
Emollients
Uremia
Histamine Antagonists
Cholestasis, Intrahepatic
Dermatitis, Atopic
Analgesia, Epidural
Drug Eruptions
Renal Dialysis
Analgesia, Obstetrical
Cholestasis
Analgesics, Opioid
Histamine H1 Antagonists, Non-Sedating
Phototherapy
Prurigo
Ichthyosis
Neurodermatitis
Morphine
Anion Exchange Resins
Cholagogues and Choleretics
Psychophysiologic Disorders
Hemorrhoids
Fissure in Ano
Surgical Stapling
Dengue Virus
Micronesia
Dengue
Flavivirus
Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists. (1/789)
1. Subcutaneous injection of sodium deoxycholic acid into the anterior of the back of male ddY mice elicited dose-dependent scratching of the injected site with the forepaws and hindpaws. 2. Up to 100 microg of sodium deoxycholic acid induced no significant increase in vascular permeability at the injection site as assessed by a dye leakage method. 3. Bradykinin (BK) B2 receptor antagonists, FR173657 and Hoe140, significantly decreased the frequency of scratching induced by sodium deoxycholic acid. 4. Treatment with aprotinin to inhibit tissue kallikrein reduced the scratching behaviour induced by sodium deoxycholic acid, whereas treatment with soybean trypsin inhibitor to inhibit plasma kallikrein did not. 5. Although injection of kininase II inhibitor, lisinopril together with sodium deoxycholic acid did not alter the scratching behaviour, phosphoramidon, a neutral endopeptidase inhibitor, significantly increased the frequency of scratching. 6. Homogenates of the skin excised from the backs of mice were subjected to gel-filtration column chromatography followed by an assay of kinin release by trypsin from each fraction separated. Less kinin release from the fractions containing kininogen of low molecular weight was observed in the skin injected with sodium deoxycholic acid than in normal skin. 7. The frequency of scratching after the injection of sodium deoxycholic acid in plasma kininogen-deficient Brown Norway Katholiek rats was significantly lower than that in normal rats of the same strain, Brown Norway Kitasato rats. 8. These results indicate that BK released from low-molecular-weight kininogen by tissue kallikrein, but not from high-molecular-weight kininogen by plasma kallikrein, may be involved in the scratching behaviour induced by the injection of sodium deoxycholic acid in the rodent. (+info)Observations on the use of tetracycline and niacinamide as antipruritic agents in atopic dogs. (2/789)
Tetracycline and niacinamide were administered in combination to 19 atopic dogs to determine their effectiveness in controlling pruritus. The pruritus was controlled successfully in only one dog. One dog experienced diarrhea that was severe enough to warrant stopping the medication. (+info)Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. (3/789)
BACKGROUND: Opioid-related side effects associated with intravenous patient-controlled analgesia can be reduced by a low-dose naloxone infusion. The influence of nalmefene, a pure opioid antagonist with a longer duration of action, on opioid-related side effects has not been evaluated. This study was designed to determine the dose-response relation for nalmefene for the prevention of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. METHODS: One hundred twenty women undergoing lower abdominal surgery were enrolled in the study. General anesthesia was induced using thiopental and rocuronium and maintained with desflurane, nitrous oxide, and fentanyl or sufentanil. All patients received neostigmine and glycopyrrolate to reverse residual neuromuscular blockade. No prophylactic antiemetics were administered. At the end of surgery, patients were randomized to receive saline, 15 microg nalmefene, or 25 microg nalmefene intravenously. The need for antiemetic and antipruritic drugs and the total consumption of morphine during the 24-h study were recorded. The incidences of postoperative nausea, vomiting, pruritus, and pain were recorded 30 min after patients were admitted to the postanesthesia care unit. In addition, patient remembrance of these side effects was noted at 24 h after operation. RESULTS: The need for antiemetic and antipruritic medications during the 24-h study period was significantly lower in the patients receiving nahmefene compared with those receiving placebo. However, the need to treat side effects was similar in the two nahmefene groups. Prophylactic administration of nalmefene reduced the patients remembrance of nausea and itching as assessed 24 h after operation. Although the total consumption of morphine during the 24-h study period was similar in the three groups, retrospectively patients who received nalmefene characterized their pain as less severe in the previous 24 h. CONCLUSION: Compared with placebo, prophylactic administration of nalmefene significantly decreased the need for antiemetics and antipruritic medications in patients receiving intravenous patient-controlled analgesia with morphine. (+info)Physical symptoms and quality of life in patients on chronic dialysis: results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD) (4/789)
BACKGROUND: So far, little attention has been paid to the value of dialysis adequacy for patients' quality of life (QL). Therefore we studied the impact of demographic, clinical, and dialysis characteristics on physical symptoms and perceived QL. METHODS: The study population consisted of 120 incident chronic haemodialysis (HD) and 106 peritoneal dialysis (PD) patients, starting dialysis treatment in 13 Dutch centres. Data were collected 3 months after the start of dialysis. Nine physical symptoms were assessed with a self-administered questionnaire. Patient's self-assessment of QL was measured with the 36-item MOS Short Form (SF-36). RESULTS: The most common symptoms in HD and PD were fatigue (respectively 82 and 87%) and itching (73 and 68%). In HD only a medium to high comorbidity--age risk index was associated with greater symptom burden. In PD also a lower percentage lean body mass, a lower rGFR, and past episodes of underhydration were associated with greater symptom burden. The explained variance by these variables was only 12% in HD and 21% in PD. However, greater symptom burden explained a substantial additional amount of impaired physical and mental QL on top of demographics and clinical status. Dialysis variables were associated neither with symptoms nor with QL. CONCLUSION: Symptom burden can be explained to a limited extent by demographic and clinical variables and not by dialysis characteristics. Addition of symptom burden to the other variables makes it possible to explain one-third of perceived QL. This underlines the importance of symptom reduction in order to improve patient's QL. (+info)Comparison of intrathecal and epidural diamorphine for elective caesarean section using a combined spinal-epidural technique. (5/789)
To assess calculated equivalent doses of intrathecal and epidural opioids for elective Caesarean section in terms of quality and duration of analgesia, and incidence of side effects, we have compared 50 patients, allocated randomly to one of two groups to receive either diamorphine 0.25 mg intrathecally (group 1) or 5 mg epidurally (group 2), in addition to intrathecal bupivacaine 10 mg, using a combined spinal-epidural technique. There was no significant difference in duration of analgesia between groups (group 1 mean 14.6 (SD 5.9) h, group 2 14.2 (6.5) h; mean difference 0.8 h; 95% Cl -2.8-4.5; P = 0.65) or quality of analgesia (VAPS and VRS scores). The degree of pruritus was similar in both groups (80-88%) but the incidence of postoperative nausea and vomiting was significantly higher in the epidural group (24% vs 4%; P < 0.05). Intrathecal diamorphine 0.25 mg produced the same duration and quality of postoperative analgesia as epidural diamorphine 5 mg for elective Caesarean section but with significantly less nausea and vomiting. (+info)Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. (6/789)
The inherited mechanobullous disease, dystrophic epidermolysis bullosa, is caused by type VII collagen gene (COL7A1) mutations. We studied six unrelated patients with a distinct clinical subtype of this disease, epidermolysis bullosa pruriginosa, characterized by pruritus, excoriated prurigo nodules, and skin fragility. Mutation analysis using polymerase chain reaction amplification of genomic DNA, heteroduplex analysis and direct nucleotide sequencing demonstrated pathogenetic COL7A1 mutations in each case. Four patients had a glycine substitution mutation on one COL7A1 allele (G1791E, G2242R, G2369S, and G2713R), a fifth was a compound heterozygote for a splice site mutation (5532 + 1G-to-A) and a single base pair deletion (7786delG), and a sixth patient was heterozygous for an out-of-frame deletion mutation (6863del16). This study shows that the molecular pathology in patients with the distinctive clinical features of epidermolysis bullosa pruriginosa is heterogeneous and suggests that other factors, in addition to the inherent COL7A1 mutation(s), may be responsible for an epidermolysis bullosa pruriginosa phenotype. (+info)Patient-controlled analgesia: epidural fentanyl and i.v. morphine compared after caesarean section. (7/789)
We have compared patient-controlled epidural fentanyl (PCEF) and patient-controlled i.v. morphine (PCIM) after Caesarean section in 84 patients, in a randomized, double-blind study. All patients had an epidural and an i.v. patient-controlled analgesia (PCA) device, one of which delivered normal saline. Group PCEF received epidural fentanyl 20 micrograms with a 10-min lockout. Group PCIM received i.v. morphine 1 mg with a 5-min lockout. PCA use was lower for PCEF patients (P = 0.0007). The highest pain score recorded at rest for PCEF patients was median 20 (interquartile range 10-33) mm compared with 32 (14-52) mm for PCIM patients (P = 0.02). The highest pain score recorded on coughing was 31 (21-41) mm with PCEF compared with 56 (30-71) mm for PCIM (P = 0.001). There was less nausea (P = 0.02) and drowsiness (P = 0.0003) with PCEF. There was no difference in the overall incidence and severity of pruritus (P = 0.77). However, pruritus started earlier with PCEF. (+info)Management of opioid-induced pruritus: a role for 5-HT3 antagonists? (8/789)
We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study. Using a 'human model' of opioid-induced pruritus, 80 ASA I-II patients about to undergo routine surgery were given either ondansetron 4 mg i.v. or 0.9% saline i.v. (40 in each group), 30 min before alfentanil 10 mg kg-1 i.v. During the following 5 min, patients were observed for signs of perinasal scratching and at 5 min were asked about symptoms of pruritus. The study was then terminated and anaesthesia was induced. There was a significant reduction in the incidence of scratching in patients receiving ondansetron compared with placebo (42.5% vs 70%, respectively, P = 0.013). The incidence of itching in the ondansetron group was less than that in the placebo group but this was not statistically significant (30% vs 42.5%, respectively, P = 0.245). We conclude that the 5-HT3 antagonist ondansetron may have a role in the management of opioid-induced pruritus. (+info)Pruritus can be acute or chronic, depending on its duration and severity. Acute pruritus is usually caused by a specific trigger, such as an allergic reaction or insect bite, and resolves once the underlying cause is treated or subsides. Chronic pruritus, on the other hand, can persist for months or even years and may be more challenging to diagnose and treat.
Some common causes of pruritus include:
1. Skin disorders such as atopic dermatitis, psoriasis, eczema, and contact dermatitis.
2. Allergic reactions to medications, insect bites, or food.
3. Certain systemic diseases such as kidney disease, liver disease, and thyroid disorders.
4. Pregnancy-related itching (obstetric pruritus).
5. Cancer and its treatment, particularly chemotherapy-induced itching.
6. Nerve disorders such as peripheral neuropathy and multiple sclerosis.
7. Infections such as fungal, bacterial, or viral infections.
8. Parasitic infestations such as scabies and lice.
Managing pruritus can be challenging, as it often leads to a vicious cycle of scratching and skin damage, which can exacerbate the itching sensation. Treatment options for pruritus depend on the underlying cause, but may include topical corticosteroids, oral antihistamines, immunomodulatory drugs, and other medications. In severe cases, hospitalization may be necessary to address the underlying condition and provide symptomatic relief.
In conclusion, pruritus is a common symptom with many possible causes, ranging from skin disorders to systemic diseases and infections. Diagnosis and management of pruritus require a comprehensive approach, involving both physical examination and laboratory tests to identify the underlying cause, as well as appropriate treatment options to provide relief and prevent complications.
The symptoms of pruritus ani may include:
* Intensely itchy sensation in the anus and surrounding areas
* Redness, swelling, and inflammation around the anus
* Pain or discomfort during bowel movements
* Difficulty controlling the urge to scratch the area
* Thickening and darkening of the skin around the anus (a condition known as hypertrophic anal papillae)
There are several potential causes of pruritus ani, including:
* Skin conditions such as eczema, psoriasis, or dermatitis
* Allergies to soaps, detergents, or other substances that come into contact with the skin
* Infections such as jock itch or yeast infections
* Certain medical conditions such as diabetes, kidney disease, or liver disease
* Poor hygiene or poor wiping techniques after bowel movements
Treatment for pruritus ani depends on the underlying cause and may include:
* Topical creams or ointments to reduce itching and inflammation
* Oral medications such as antibiotics or antihistamines
* Good hygiene practices, such as wiping the area gently after bowel movements and avoiding harsh soaps or wipes
* Avoiding scratching the area and using a cold compress to reduce itching
* In severe cases, steroid injections or surgery may be necessary.
Preventative measures for pruritus ani include:
* Practicing good hygiene, such as wiping the area gently after bowel movements and avoiding harsh soaps or wipes
* Avoiding scratching the area and using a cold compress to reduce itching
* Wearing loose, breathable clothing to reduce irritation and sweating
* Avoiding tight-fitting underwear or pantyhose that can trap moisture and bacteria
* Using a powder or talcum puff to help absorb moisture and reduce itching.
It is important to seek medical attention if symptoms persist or worsen over time, as pruritus ani can lead to complications such as skin thickening, infection, and scarring.
The exact cause of pruritus vulvae is not known, but it is believed to be related to hormonal changes, allergies, infections, or skin conditions such as eczema or psoriasis. Certain products or substances, such as soaps, douches, or spermicides, can also irritate the area and exacerbate symptoms.
There are several risk factors for developing pruritus vulvae, including:
* Hormonal changes during menstruation, pregnancy, or menopause
* Allergies to certain substances in soaps, douches, or spermicides
* Skin conditions such as eczema or psoriasis
* Infections such as yeast infections or bacterial vaginosis
* Sexually transmitted infections (STIs)
There is no specific treatment for pruritus vulvae, but symptoms can be managed with the following measures:
1. Avoiding irritants and allergens that may exacerbate symptoms
2. Using gentle, fragrance-free cleansers and avoiding harsh soaps or douches
3. Applying cool compresses or over-the-counter anti-itch creams or ointments to the affected area
4. Wearing breathable, loose-fitting clothing and avoiding tight undergarments that may irritate the area
5. Practicing good hygiene and wiping gently after using the bathroom
6. Avoiding sexual intercourse during severe episodes of itching
7. Considering medications such as antihistamines, corticosteroids, or antibiotics if symptoms are severe or persistent.
It is important to seek medical attention if symptoms persist or worsen over time, as pruritus vulvae can be a sign of an underlying infection or other condition that requires treatment.
Treatment for uremia typically involves dialysis or kidney transplantation to remove excess urea from the blood and restore normal kidney function. In some cases, medications may be prescribed to help manage symptoms such as high blood pressure, anemia, or electrolyte imbalances.
The term "uremia" is derived from the Greek words "oura," meaning "urea," and "emia," meaning "in the blood." It was first used in the medical literature in the late 19th century to describe a condition caused by excess urea in the blood. Today, it remains an important diagnostic term in nephrology and is often used interchangeably with the term "uremic syndrome."
Also known as eczema or atopic eczema.
Dermatitis, Atopic is a common condition that affects people of all ages but is most prevalent in children. It is often associated with other atopic conditions such as asthma and allergies. The exact cause of dermatitis, atopic is not known, but it is thought to involve a combination of genetic and environmental factors.
Symptoms of Dermatitis, Atopic:
* Redness and dryness of the skin
* Scaling and flaking of the skin
* Itching and burning sensations
* Thickening and pigmentation of the skin
* Small blisters or weeping sores
Atopic dermatitis can occur anywhere on the body but is most commonly found on the face, neck, hands, and feet.
Treatment for Dermatitis, Atopic:
* Moisturizers to keep the skin hydrated and reduce dryness
* Topical corticosteroids to reduce inflammation
* Antihistamines to relieve itching
* Phototherapy with ultraviolet light
* Oral immunomodulators for severe cases
It is important to note that dermatitis, atopic is a chronic condition, and treatment should be ongoing. Flare-ups may occur, and adjustments to the treatment plan may be necessary.
Prevention of Dermatitis, Atopic:
* Avoiding triggers such as soaps, detergents, and stress
* Keeping the skin well-moisturized
* Avoiding extreme temperatures and humidity
* Wearing soft, breathable clothing
* Using mild cleansers and avoiding harsh chemicals
Early diagnosis and treatment of dermatitis, atopic can help improve the quality of life for those affected. It is important to work with a healthcare professional to develop an appropriate treatment plan and manage symptoms effectively.
Types of Drug Eruptions:
1. Maculopapular exanthema (MPE): This is a common type of drug eruption characterized by flat, red patches on the skin that may be accompanied by small bumps or hives. MPE typically occurs within 1-2 weeks of starting a new medication and resolves once the medication is discontinued.
2. Stevens-Johnson syndrome (SJS): This is a more severe type of drug eruption that can cause blisters, skin sloughing, and mucosal lesions. SJS typically occurs within 2-4 weeks of starting a new medication and can be life-threatening in some cases.
3. Toxic epidermal necrolysis (TEN): This is a severe, life-threatening type of drug eruption that can cause widespread skin death and mucosal lesions. TEN typically occurs within 2-4 weeks of starting a new medication and requires immediate hospitalization and treatment.
Causes of Drug Eruptions:
1. Allergic reactions to medications: This is the most common cause of drug eruptions. The body's immune system overreacts to certain medications, leading to skin symptoms.
2. Adverse effects of medications: Certain medications can cause skin symptoms as a side effect, even if the person is not allergic to them.
3. Infections: Bacterial, fungal, or viral infections can cause drug eruptions, particularly if the medication is used to treat the infection.
4. Autoimmune disorders: Certain autoimmune disorders, such as lupus or rheumatoid arthritis, can increase the risk of developing drug eruptions.
Diagnosis and Treatment of Drug Eruptions:
1. Medical history and physical examination: A thorough medical history and physical examination are essential to diagnose a drug eruption. The healthcare provider will look for patterns of skin symptoms that may be related to a specific medication.
2. Skin biopsy: In some cases, a skin biopsy may be necessary to confirm the diagnosis of a drug eruption and to rule out other conditions.
3. Medication history: The healthcare provider will ask about all medications taken by the patient, including over-the-counter medications and supplements.
4. Treatment: Depending on the severity of the drug eruption, treatment may include stopping the offending medication, administering corticosteroids or other immunosuppressive medications, and providing supportive care to manage symptoms such as itching, pain, and infection. In severe cases, hospitalization may be necessary.
5. Monitoring: Patients with a history of drug eruptions should be closely monitored by their healthcare provider when starting new medications, and any changes in their skin should be reported promptly.
Prevention of Drug Eruptions:
1. Allergy testing: Before starting a new medication, the healthcare provider may perform allergy testing to determine the patient's sensitivity to specific medications.
2. Medication history: The healthcare provider should take a thorough medication history to identify potential allergens and avoid prescribing similar medications that may cause an adverse reaction.
3. Gradual introduction of new medications: When starting a new medication, it is recommended to introduce the medication gradually in small doses to monitor for any signs of an adverse reaction.
4. Monitoring: Patients should be closely monitored when starting new medications, and any changes in their skin or symptoms should be reported promptly to their healthcare provider.
5. Avoiding certain medications: In some cases, it may be necessary to avoid certain medications that are more likely to cause a drug eruption based on the patient's medical history and other factors.
Conclusion:
Drug eruptions can present with various symptoms and can be challenging to diagnose. A thorough medical history and physical examination are essential to diagnose a drug eruption. Treatment depends on the severity of the reaction and may include stopping the offending medication, administering corticosteroids, and providing supportive care. Prevention is key, and healthcare providers should be aware of potential allergens and take steps to minimize the risk of adverse reactions. By being vigilant and proactive, healthcare providers can help prevent drug eruptions and ensure the best possible outcomes for their patients.
Some common types of skin diseases include:
1. Acne: a condition characterized by oil clogged pores, pimples, and other blemishes on the skin.
2. Eczema: a chronic inflammatory skin condition that causes dry, itchy, and scaly patches on the skin.
3. Psoriasis: a chronic autoimmune skin condition characterized by red, scaly patches on the skin.
4. Dermatitis: a term used to describe inflammation of the skin, often caused by allergies or irritants.
5. Skin cancer: a type of cancer that affects the skin cells, often caused by exposure to UV radiation from the sun or tanning beds.
6. Melanoma: the most serious type of skin cancer, characterized by a mole that changes in size, shape, or color.
7. Vitiligo: a condition in which white patches develop on the skin due to the loss of pigment-producing cells.
8. Alopecia: a condition characterized by hair loss, often caused by autoimmune disorders or genetics.
9. Nail diseases: conditions that affect the nails, such as fungal infections, brittleness, and thickening.
10. Mucous membrane diseases: conditions that affect the mucous membranes, such as ulcers, inflammation, and cancer.
Skin diseases can be diagnosed through a combination of physical examination, medical history, and diagnostic tests such as biopsies or blood tests. Treatment options vary depending on the specific condition and may include topical creams or ointments, oral medications, light therapy, or surgery.
Preventive measures to reduce the risk of skin diseases include protecting the skin from UV radiation, using sunscreen, wearing protective clothing, and avoiding exposure to known allergens or irritants. Early detection and treatment can help prevent complications and improve outcomes for many skin conditions.
There are several types of cholestasis, including:
1. Obstructive cholestasis: This occurs when there is a blockage in the bile ducts, preventing bile from flowing freely from the liver.
2. Metabolic cholestasis: This is caused by a problem with the metabolism of bile acids in the liver.
3. Inflammatory cholestasis: This occurs when there is inflammation in the liver, which can cause scarring and impair bile flow.
4. Idiopathic cholestasis: This type of cholestasis has no identifiable cause.
Treatment for cholestasis depends on the underlying cause, but may include medications to improve bile flow, dissolve gallstones, or reduce inflammation. In severe cases, a liver transplant may be necessary. Early diagnosis and treatment can help to manage symptoms and prevent complications of cholestasis.
* Intensive itching or burning sensation on the skin
* Redness, inflammation, or scaling of the skin
* Small, raised bumps or blisters that may ooze fluid
* Skin thickening or pigmentation due to repeated scratching
Prurigo can be difficult to diagnose, as it can mimic other skin conditions such as eczema, psoriasis, or dermatitis. A healthcare provider will typically perform a physical examination and may order diagnostic tests such as skin scrapings, biopsies, or blood tests to determine the underlying cause of the condition.
Treatment for prurigo depends on the underlying cause, but it may include topical or oral medications, such as antihistamines, corticosteroids, or antibiotics. In severe cases, phototherapy or immunomodulatory therapy may be necessary. It is important to seek medical attention if you suspect you have prurigo, as the condition can lead to infection and scarring if left untreated.
Symptoms of ichthyosis can include:
* Thickened, scaly skin on the arms, legs, back, and chest
* Redness and itching
* Cracking and splitting of the skin
* Increased risk of infection
* Respiratory problems
Treatment for ichthyosis typically involves the use of topical creams and ointments to help soften and hydrate the skin, as well as oral medications to reduce inflammation and itching. In severe cases, phototherapy or systemic corticosteroids may be necessary.
In addition to these medical treatments, there are also several home remedies and lifestyle modifications that can help manage the symptoms of ichthyosis. These include:
* Moisturizing regularly with a fragrance-free moisturizer
* Avoiding harsh soaps and cleansers
* Using lukewarm water when showering or bathing
* Applying cool compresses to the skin to reduce redness and inflammation
* Wearing loose, breathable clothing to avoid irritating the skin
* Protecting the skin from extreme temperatures and environmental stressors.
Neurodermatitis can affect anyone, but it is most common in infants and children, and those with a family history of atopic conditions such as asthma, eczema, or allergies. The exact cause of neurodermatitis is not fully understood, but it is thought to involve a combination of genetic and environmental factors.
Symptoms of neurodermatitis can vary in severity and may include:
* Itching, which can be intense and disrupt daily activities
* Redness and inflammation
* Dry, scaly skin that may ooze or crust over
* Thickening and pigmentation of the skin
* Sleep disturbances due to itching or discomfort
Neurodermatitis can be challenging to treat, but there are several effective therapies available. These include topical corticosteroids, immunomodulators, and anti-inflammatory medications, as well as lifestyle changes such as avoiding triggers, using gentle skin care products, and keeping the skin moisturized.
In severe cases of neurodermatitis, complications such as infection, scarring, and emotional distress may arise. It is essential to seek medical advice if symptoms persist or worsen over time. With proper treatment and self-care, however, many people with neurodermatitis can experience significant improvement in their quality of life.
1. Somatic symptom disorder: This condition is characterized by persistent and excessive thoughts or concerns about physical symptoms, such as pain or gastrointestinal issues, despite medical evaluation and reassurance that no underlying medical condition exists.
2. Illness anxiety disorder: Formerly known as hypochondriasis, this disorder is characterized by an excessive preoccupation with the fear of having or acquiring a serious illness, despite evidence to the contrary.
3. Conversion disorder: This condition is characterized by symptoms that are not readily explainable by a medical or neurological condition, such as paralysis, blindness, or difficulty speaking. The symptoms are thought to be a manifestation of psychological conflicts or stressors.
4. Factitious disorder: Also known as Munchausen syndrome, this condition is characterized by the deliberate production or feigning of symptoms in order to gain attention, sympathy, or other forms of support.
5. Hypochondriasis: This condition is characterized by an excessive preoccupation with the fear of having or acquiring a serious illness, despite evidence to the contrary.
6. Health anxiety disorder: This condition is characterized by an excessive preoccupation with the fear of having or acquiring a serious illness, despite evidence to the contrary.
7. Medical phobia: This condition is characterized by an excessive fear of medical procedures or healthcare settings, which can lead to avoidance of necessary medical care and potential harm as a result.
8. Pain disorder: This condition is characterized by persistent and excessive pain that cannot be fully explained by a medical condition or injury. The pain can have a significant impact on an individual's daily life and functioning.
9. Psychogenic non-epileptic seizures: These are seizures that are not caused by a medical or neurological condition, but rather by psychological factors such as stress, anxiety, or other forms of emotional distress.
10. Somatic symptom disorder: This condition is characterized by persistent and excessive preoccupation with physical symptoms, such as pain, fatigue, or gastrointestinal issues, despite medical evidence that the symptoms are not caused by a medical condition or injury.
It's important to note that while these conditions are distinct from one another, they can sometimes overlap or co-occur, and it may be necessary to rule out other potential causes of the patient's symptoms before making a diagnosis. Additionally, individuals with mental health conditions may be at higher risk for developing somatoform disorders due to the emotional distress and maladaptive coping strategies that can accompany these conditions.
Hemorrhoids are caused by increased pressure on the veins in the rectum and anus, which can be due to a variety of factors such as constipation, pregnancy, childbirth, obesity, and aging. The pressure causes the veins to swell and become irritated, leading to symptoms such as:
* Painless bleeding during bowel movements
* Pain or discomfort during bowel movements
* Itching or irritation in the anal area
* A lump near the anus
* Difficulty passing stool
There are several methods for treating hemorrhoids, including:
* Dietary changes: Eating a high-fiber diet can help soften stools and reduce pressure on the veins in the rectum and anus.
* Medications: Over-the-counter medications such as hydrocortisone creams and suppositories can help reduce itching and inflammation.
* Internal hemorrhoids: Self-care measures, such as increasing fiber intake and drinking plenty of fluids, may be sufficient to treat internal hemorrhoids. However, if symptoms persist or worsen, medical treatment may be necessary.
* External hemorrhoids: Treatment for external hemorrhoids may include warm compresses, elevation of the affected area, and pain management with medication. In severe cases, surgery may be required.
It is important to note that while hemorrhoids are not dangerous, they can be uncomfortable and disrupt daily life. If symptoms persist or worsen, it is important to seek medical attention to rule out other conditions and receive proper treatment.
* Pain during bowel movements
* Bleeding during bowel movements
* Itching or burning sensation around the anus
* Discharge of pus from the anus
* Redness and swelling around the anus
Fissure in ano can be caused by straining during bowel movements, constipation, diarrhea, or any other condition that puts pressure on the anal skin. Treatment for fissure in ano includes:
* Increasing fiber intake to soften stools and reduce constipation
* Drinking plenty of water to keep the stools soft
* Avoiding straining during bowel movements
* Using stool softeners or laxatives if necessary
* Applying a topical cream or ointment to reduce pain and promote healing
* In some cases, prescription medications may be used to treat fissure in ano.
It is important to seek medical attention if you experience any symptoms of fissure in ano, as it can lead to complications such as infection or narrowing of the anus if left untreated. A healthcare professional can diagnose fissure in ano by examining the anus and performing a physical rectal examination.
In addition to medical treatment, there are some self-care measures that can help manage symptoms of fissure in ano, such as:
* Soaking in a warm bath for 10-15 minutes several times a day to reduce pain and promote healing
* Applying a cold compress or ice pack to the affected area to reduce pain and swelling
* Avoiding spicy or irritating foods and drinks
* Using stool softeners or laxatives as directed by a healthcare professional.
It is important to note that fissure in ano can be a recurring condition, so it is important to take steps to prevent recurrence, such as maintaining a high fiber diet and drinking plenty of fluids.
Flavivirus infections can cause a range of symptoms, including fever, headache, muscle and joint pain, and skin rashes. In severe cases, these infections can lead to hemorrhagic fever, which can be fatal.
The transmission of flaviviruses is typically through the bite of an infected mosquito or other insect vectors, although some viruses can also be transmitted through blood transfusions or organ transplantation.
There is no specific treatment for flavivirus infections, but supportive care such as hydration, pain relief, and antipyretic medications may be provided to manage symptoms. Prevention includes avoiding mosquito bites by using insect repellents, wearing protective clothing, and eliminating standing water around homes and communities to reduce the number of mosquito breeding sites.
In addition, vaccines are available for some flaviviruses, such as yellow fever and dengue fever, which can provide protection against infection.
Overall, flavivirus infections are a significant public health concern, particularly in tropical and subtropical regions where these viruses are most commonly found.
Symptoms of dengue fever typically begin within 2-7 days after the bite of an infected mosquito and can include:
* High fever
* Severe headache
* Pain behind the eyes
* Severe joint and muscle pain
* Rash
* Fatigue
* Nausea
* Vomiting
In some cases, dengue fever can develop into a more severe form of the disease, known as dengue hemorrhagic fever (DHF), which can be life-threatening. Symptoms of DHF include:
* Severe abdominal pain
* Vomiting
* Diarrhea
* Bleeding from the nose, gums, or under the skin
* Easy bruising
* Petechiae (small red spots on the skin)
* Black stools
* Decreased urine output
Dengue fever is diagnosed based on a combination of symptoms, physical examination findings, and laboratory tests. Treatment for dengue fever is primarily focused on relieving symptoms and managing fluid and electrolyte imbalances. There is no specific treatment for the virus itself, but early detection and proper medical care can significantly lower the risk of complications and death.
Prevention of dengue fever relies on measures to prevent mosquito bites, such as using insect repellents, wearing protective clothing, and eliminating standing water around homes and communities to reduce the breeding of mosquitoes. Vaccines against dengue fever are also being developed, but none are currently available for widespread use.
In summary, dengue is a viral disease that is transmitted to humans through the bite of infected mosquitoes and can cause a range of symptoms from mild to severe. Early detection and proper medical care are essential to prevent complications and death from dengue fever. Prevention of dengue relies on measures to prevent mosquito bites and eliminating standing water around homes and communities.
References:
1. World Health Organization. (2020). Dengue and severe dengue. Retrieved from
2. Centers for Disease Control and Prevention. (2020). Dengue fever: Background. Retrieved from
3. Mayo Clinic. (2020). Dengue fever. Retrieved from
4. MedlinePlus. (2020). Dengue fever. Retrieved from
A highly contagious and common eye infection caused by a virus, which inflames the conjunctiva, the membrane that covers the white part of the eye and the inside of the eyelids. It is also known as pinkeye or Madras eye. Symptoms include redness, discharge, itching, tearing, and sensitivity to light. Treatment includes antiviral medication, artificial tears, and good hygiene practices.
This definition of 'Conjunctivitis, Viral' is intended to be as accurate as possible, and is based on the current state of medical knowledge about the topic. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about 'Conjunctivitis, Viral', please consult a qualified healthcare provider.
Pruritus scroti
Pruritus vulvae
Cholestatic pruritus
Uremic pruritus
Pruritus ani
Psychogenic pruritus
Senile pruritus
Brachioradial pruritus
Prion pruritus
Aquagenic pruritus
Scalp pruritus
Drug-induced pruritus
HIV-associated pruritus
Hydroxyethyl starch-induced pruritus
Pruritus of genital organs
Itch
Prurigo
Antipruritic
Lichen simplex chronicus
Hypervitaminosis A
John Lockhart-Mummery
Glossary of diabetes
Skin condition
Lacosamide
Anti-seborrheic
Progressive familial intrahepatic cholestasis
Cholestasis
Florid cutaneous papillomatosis
Chloroquine
Corneocyte
Itching | Pruritus | Itchy skin | MedlinePlus
Neuroanatomic Signatures in Brachioradial Pruritus, Chronic Prurigo, and Atopic Dermatitis. - International Association for the...
New Drugs and Therapies in 2022: Acne, Rosacea, and Pruritus
Inhalant Allergies and Pruritus in Horses - Veterinary Partner - VIN
Pruritus - COLORADO NORML
5-D Itch Scale - PRURITUS RESOURCES
pruritus Archives - Balance Integrative Health & Wellness
Big thinking | Nature
Pruritus Antidotes Market Key Players, Competitive Landscape,...
Why Do Hemorrhoids Itch?
Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum....
Two Cases of Recurrent Episodes of Angio Edema Without Urticaria or Pruritus | QScience.com
IMSEAR at SEARO: Role of intravenous naloxone in severe pruritus of acute cholestasis.
Stoma Dermatitis: Prevalent but Often Overlooked
MC2-25-C1 new drug for uremic pruritus starts phase II clinical trial - ADC Technologies
Other Anal Conditions: Fissures, Abscess, Pruritus | Current Medical Diagnosis & Treatment 2021 | AccessMedicine | McGraw Hill...
Flecainide: Arrhythmia Uses, Warnings, Side Effects, Dosage
Atopic Dermatitis in Emergency Medicine Clinical Presentation: History, Physical Examination, Complications
Cefaclor Extended Release Tablets: PI - Drugs.com
RXQ RX J
Uremia Treatment & Management: Approach Considerations, Dialysis, Treatment of Hyperkalemia
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. - Study Results -...
Varicose Veins and Spider Veins: Practice Essentials, Background, Pathophysiology
Table - Detection of Zika Virus in April 2013 Patient Samples, Rio de Janeiro, Brazil - Volume 23, Number 12-December 2017 -...
Can cancer cause itchy skin? Types, treatment, and other causes
Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis
DailyMed - CLOFARABINE injection
Dermatologic Manifestations of Renal Disease: Overview, Dermatologic Manifestations of Diseases Associated With ESRD,...
Uremic pruritus5
- Most recently, researchers at Wroclaw, Poland's University of Medicine, Department of Dermatology, reported that application of an endocannabinoid-based topical cream reduced uremic pruritus and xerosis (abnormal dryness of the skin) in hemodialysis patients. (coloradonorml.org)
- 2005. Efficacy and tolerance of the cream containing structured physiological lipid endocannabinoids in the treatment of uremic pruritus: a preliminary study . (coloradonorml.org)
- Naltrexone does not relieve uremic pruritus. (kidneynews.org)
- CKD-aP, also known as uremic pruritus, is a persistent systemic pruritus in which recurrent episodes of moderate-to-severe chronic pruritus severely reduce the patient's quality of life, can lead to depression, and increase the overall risk of death. (adcreviews.com)
- Nalbuphine hydrochloride, a mu-opioid receptor antagonist and kappa-opioid receptor agonist approved as an analgesic, is used off-label for opioid-induced pruritus and may have an effect on uremic pruritus. (medscape.com)
Severe pruritus7
- On October 6, 1985, a Paterson, New Jersey, Fire Department ambulance responded to a call reporting two people with severe pruritus. (cdc.gov)
- Shown to work for itch independent of histamine, strontium is an ingredient that has been found to help mitigate itch in patients with moderate to severe pruritus, regardless of pathogenesis. (dermatologytimes.com)
- IMSEAR at SEARO: Role of intravenous naloxone in severe pruritus of acute cholestasis. (who.int)
- Joshi Gunjan G, Thakur B S, Sircar Shohini, Namdeo Arvind, Jain Ajay K. Role of intravenous naloxone in severe pruritus of acute cholestasis. (who.int)
- Twenty-two patients with severe pruritus (based on visual analogue scale [VAS] score of 0-100 and associated symptoms) were treated with intravenous naloxone (0.4 mg every 8 hours) for at least 48 hours. (who.int)
- The trial was designed to evaluate the safety and efficacy of MC2-25 cream in patients with chronic kidney disease (CKD-aP)-associated moderate to severe pruritus stage III-V. (adcreviews.com)
- In August 2021, the FDA approved Korsuva for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis, the first treatment for pruritus in chronic kidney disease dialysis patients. (adcreviews.com)
Type of pruritus1
- This type of pruritus likely occurs because of an overproduction of immune cells that trigger the release of chemicals called histamines. (medicalnewstoday.com)
Cholestatic8
- BAM8-22 and its receptor MRGPRX1 may attribute to cholestatic pruritus. (nih.gov)
- Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus. (nih.gov)
- Writing in the August 2002 issue of the American Journal of Gastroentrology , investigators from the University of Miami Department of Medicine reported successful treatment of pruritus with 5 mg of THC in three patients with cholestatic liver disease. (coloradonorml.org)
- Delta-9-tetrahydrocannabinol may be an effective alternative in patients with intractable cholestatic pruritus," investigators concluded. (coloradonorml.org)
- 2002. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease . (coloradonorml.org)
- Pruritus is a well-known manifestation of various cholestatic disorders. (who.int)
- Viral hepatitis E was found to be the most common etiology for cholestatic pruritus (n=12). (who.int)
- Naloxone is safe and efficacious in symptomatic improvement in cholestatic pruritus. (who.int)
Atopic Dermatitis3
- Neuroanatomic Signatures in Brachioradial Pruritus, Chronic Prurigo, and Atopic Dermatitis. (iasp-pain.org)
- The hallmarks of atopic dermatitis are intense pruritus, chronic eczematous skin lesions, and epidermal thickening and hypertrophy. (medscape.com)
- Atopic dermatitis begins with intense pruritus, leading the patient to scratch, which results in the characteristic rash. (medscape.com)
Itching6
- Itching ( pruritus ) is a common symptom associated with numerous skin diseases, as well as a secondary symptom of numerous serious conditions such as renal failure and liver disease. (coloradonorml.org)
- 4] Three weeks of twice-daily application of the cream "completely eliminated" pruritus in 38 percent of trial subjects and "significantly reduced" itching in others. (coloradonorml.org)
- Recent emergence of TRP channels as a drug target for treatment of itching is a major disruptive finding in pruritus sector. (sharkbow.com)
- Anal itching is also referred to as pruritus ani which could be triggered by a number of conditions aside from hemorrhoids. (healthline.com)
- Therapeutics for preventing or treating pruritus/itching. (nih.gov)
- A 2018 study involving 16,925 people found that the participants with generalized skin itching, or pruritus, were more likely to also have cancer than those who did not have pruritus. (medicalnewstoday.com)
Symptom2
- UNLABELLED A challenge in obstetrics is to distinguish pathological symptoms from those associated with normal changes of pregnancy , typified by the need to differentiate whether gestational pruritus of the skin is an early symptom of intrahepatic cholestasis of pregnancy (ICP) or due to benign pruritus gravidarum. (bvsalud.org)
- Scabies The predominant symptom of scabies is pruritus. (cdc.gov)
Itch7
- Knockout of OSMR in sensory neurons attenuated OSM-sensitized itch and inflammatory itch in mice, and pharmacological antagonism of the OSMR complex effectively alleviated pruritus in experimental inflammatory dermatitis in a rodent model. (nih.gov)
- 2006 . Frontiers in pruritus research: scratching the brain for more effective itch therapy . (coloradonorml.org)
- The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. (pruritussymposium.de)
- The 5-D itch scale: a new measure of pruritus. (pruritussymposium.de)
- Concentrations of progesterone sulfates were associated with itch severity and, in combination with autotaxin, distinguished pregnant women with itch that would subsequently develop ICP from pruritus gravidarum (group 2 ICP n = 41, pruritus gravidarum n = 14). (bvsalud.org)
- Delineation of a progesterone sulfate -TGR5 pruritus axis identifies a therapeutic target for itch management in ICP. (bvsalud.org)
- These lesions are characterized by intense pruritus that ceases when pain replaces itch. (medscape.com)
Therapeutic2
- Continued research has led to several exciting therapeutic developments in drug delivery technologies as well as new and experimental medications for a wide spectrum of dermatological diseases and conditions including acne, rosacea, and pruritus. (dermatologytimes.com)
- The study covers therapeutic agents for 'Pruritus' - an unpleasant sensation that stimulates desire to scratch the skin. (sharkbow.com)
Prevalence3
- High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario, and drug development pressure on pharmaceuticals due to upcoming patent expiries are key factors contributing to high CAGR of Pruritus Antidotes during forecast period. (sharkbow.com)
- Rising prevalence of target diseases, unmet needs of pruritus patients pushing the drug development, significant focus of pharmaceutical companies on development of novel mechanisms based pruritus drugs, upcoming patent expiry, availability of public as well private funds for research, and favorable regulatory scenario, are some of the key factors propelling market growth in the industry. (sharkbow.com)
- High pruritus prevalence across the globe is the key factor to accelerate the market growth during forecast period across all regions. (sharkbow.com)
Chronic1
- Approved drug for the treatment of pruritus associated with stage III-IV chronic kidney disease. (adcreviews.com)
Patients4
- Patients suffering from several dermatologic diseases and conditions including acne, rosacea, and pruritus can largely benefit from the new and exciting therapies and treatment modalities that have recently become available. (dermatologytimes.com)
- Following evening cannabinoid administration, all three patients reported a decrease in pruritus, as well as "marked improvement" in sleep and were eventually able to return to work. (coloradonorml.org)
- Even in severe cases with widespread skin involvement and extensive oozing and crusting, pruritus is still the patients' major concern and a significant burden of the disease," Legat wrote in Frontiers in Medicine . (medpagetoday.com)
- CIO Responsible for this publication: National Center for Prevention Services, Division of Sexually Transmitted Diseases and HIV Prevention ECTOPARASITIC INFECTIONS Pediculosis Pubis Patients with pediculosis pubis (pubic lice) usually seek medical attention because of pruritus. (cdc.gov)
Treatment4
- A review of the scientific literature reveals three clinical trials investigating the use of cannabinoids in the treatment of pruritus. (coloradonorml.org)
- In line with this, TRP channel antagonists, TRPM8 agonists are some of the emerging TRP channel modulation mechanisms that can be for could be used for pruritus treatment. (sharkbow.com)
- A new category of drug for pruritus treatment. (nih.gov)
- Treatment for refractory pruritus remains less clearly defined, according to these authors. (medscape.com)
20211
- Regional analysis covers in-depth analysis of analysis of the revenue, market share, and growth rate of the global Pruritus Antidotes market in each region for the forecast period of 2021-2028. (sharkbow.com)
Outcomes1
- We performed a meta-analysis to evaluate the effects of ursodeoxycholic acid (UDCA) on pruritus, liver test results, and outcomes of babies born to women with intrahepatic cholestasis of pregnancy (ICP). (nih.gov)
Bile1
- With GI cancers, pruritus occurs due to blockage of the bile ducts connecting the liver and the small intestine . (medicalnewstoday.com)
Researchers1
- The researchers also note that Black people with pruritus are more likely than white people to have skin, soft tissue, and blood cancers . (medicalnewstoday.com)
Study1
- This prospective, uncontrolled study was done to determine the efficacy of intravenous naloxone in pruritus of acute cholestasis. (who.int)
Score1
- The primary efficacy endpoint of the trial was the change from baseline in Weekly Mean Worst Pruritus Numerical Score (WI-NRS) over 12 weeks. (adcreviews.com)
Weeks2
Patient1
- Medical palliation of the jaundiced patient with pruritus. (nih.gov)
High1
- Our discovery that sulfated progesterone metabolites are a prognostic indicator for ICP will help predict onset of ICP and distinguish it from benign pruritus gravidarum, enabling targeted obstetric care to a high- risk population . (bvsalud.org)
Types1
- Below, we discuss in more detail the types of cancer that may cause pruritus. (medicalnewstoday.com)
Percent1
- According to the current analysis of Reports and Data, the global Pruritus Antidotes market was valued at USD 12.40 Billiion in 2020 and is expected to reach USD 19.98 Billion by year 2028, at a CAGR of 6.23 percent. (sharkbow.com)
Potential1
- Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. (bvsalud.org)